Nuclear <scp>pCHK1</scp> as a potential biomarker of increased sensitivity to <scp>ATR</scp> inhibition

Vignesh Sundararajan, Tuan Zea Tan, Diana Lim, Yanfen Peng, Antje M. Wengner, Natalie Y.l. Ngoi, Anand D. Jeyasekharan, David S.p. TanThe Journal of Pathology 2022 · DOI

TL;DR

This study identifies nuclear-localized phosphorylated CHK1 (pCHK1) as a promising predictive biomarker for sensitivity to ATR inhibitors like elimusertib. By analyzing cancer cell lines, xenografts, and patient samples, the researchers found that higher nuclear pCHK1 levels correlate with better treatment response, offering a potential tool for patient selection in targeted cancer therapies.

What Problem Does This Paper Address?

Cancer cells often exhibit high levels of "replication stress" due to genomic instability and faulty DNA repair mechanisms. A promising therapeutic strategy involves targeting the DNA damage response (DDR) and replicative stress response (RSR) pathways, specifically kinases like ATR and CHK1. Inhibiting these pathways can lead to the accumulation of unrepaired DNA damage, ultimately causing cancer cell death. Elimusertib, a selective ATR inhibitor, has shown therapeutic potential, but reliable biomarkers to predict which patients will benefit most from this treatment are still lacking. This paper aims to identify such a biomarker to improve patient stratification for ATR inhibitor therapy.

Methods

The researchers employed a multi-pronged approach:

  • Gene Expression Profiling: They used NanoString's PanCancer pathway panel to analyze the expression of 770 genes in 24 cancer cell lines with varying sensitivities to elimusertib. This allowed them to identify gene signatures associated with drug response.
  • In Vitro Assays: Cell viability assays (CellTiter-Glo® and CCK-8) were used to determine the half-maximal inhibitory concentration (IC50) of elimusertib for various cell lines, quantifying their sensitivity.
  • Cell Fractionation: To investigate the subcellular localization of CHK1, whole cell lysates were separated into nuclear and cytoplasmic fractions, followed by Western blotting.
  • Cell Line-Derived Xenografts (CDX): Tumors were generated by implanting cancer cells into immunocompromised mice. These xenografts were then treated with elimusertib to assess drug response and collect tissue samples.
  • Multiplex Immunohistochemistry (IHC) / Immunofluorescence (IF): An advanced multispectral imaging system (Vectra 3) was used to simultaneously stain and quantify multiple protein markers (geminin, pATR, pCHK1, γH2AX) in xenograft tissues and patient biopsies. This technique allows for precise spatial localization and quantification of protein expression.
  • Correlation Analysis: Statistical methods, including Spearman correlation, were used to correlate gene expression and protein levels with drug sensitivity (IC50 or T/C ratios).

Datasets

  • 24 Cancer Cell Lines: A diverse panel of cell lines from various cancer types was used for initial gene expression profiling and sensitivity assays.
  • Ovarian Cancer Cell Lines: A specific panel of 15 ovarian cancer cell lines was used for detailed analysis of pCHK1 expression and sensitivity.
  • Cell Line-Derived Xenografts (CDX): 15 xenograft models were generated from these cell lines for in vivo validation.
  • Human Tumor Biopsies: Archival pre-treatment tumor tissue samples from four ovarian cancer patients treated with elimusertib were analyzed to assess the biomarker's relevance in a clinical setting.
  • GDSC2 Database: Drug sensitivity data from the Genomics of Drug Sensitivity in Cancer database was used to correlate pCHK1 levels with responses to other DDR/RSR inhibitors.

Key Insights and Ideas

  • DDR Pathway as a Sensitivity Indicator: The study strongly suggests that higher expression of DNA damage response (DDR) pathway genes is linked to increased sensitivity to ATR inhibitors. This aligns with the mechanism of action of these drugs, which exploit existing DNA repair deficiencies.
  • Nuclear pCHK1 is Key: While total CHK1 expression or its cytoplasmic localization didn't show a clear correlation, the nuclear localization of phosphorylated CHK1 (pCHK1) emerged as a critical factor. This highlights the importance of subcellular localization in predicting drug response.
  • ATR-CHK1 Axis Activation: The findings reinforce the role of the ATR-CHK1 signaling axis in mediating cellular responses to DNA damage and replication stress, and its potential as a therapeutic target.
  • Biomarker Potential: The consistent trend observed across cell lines, xenografts, and a small cohort of patient samples points towards nuclear pCHK1 as a robust predictive biomarker for ATR inhibitor efficacy.

Key Results

  • Gene Expression: 57 genes significantly correlated with elimusertib response, with DDR pathway genes showing particular enrichment in sensitive cell lines.
  • In Vitro Sensitivity: A significant negative correlation (rho = -0.5680, p = 0.0175) was found between endogenous activated CHK1 (pCHK1) levels and elimusertib IC50 in ovarian cancer cell lines, meaning higher pCHK1 correlated with lower IC50 (higher sensitivity).
  • Subcellular Localization: Elimusertib-sensitive cell lines showed significantly higher enrichment of pCHK1 in their nuclear fractions compared to resistant cell lines.
  • In Vivo Trends: In xenografts, higher nuclear pCHK1 staining showed a trend towards higher sensitivity to elimusertib (r = -0.4574, p = 0.0879).
  • Clinical Correlation: In a small cohort of ovarian cancer patients, those with stable disease (SD) after elimusertib treatment exhibited higher nuclear pCHK1 localization compared to the patient with progressive disease (PD).

Limitations and Future Work

  • Small Patient Cohort: The study acknowledges the limitation of a small cohort of patient samples for clinical validation. The authors suggest that further evaluation of nuclear pCHK1 is warranted in larger, ongoing clinical trials.
  • Validation of Antibody Specificity: While the study validated the pCHK1 antibody's specificity using hydroxyurea treatment and CHK1 knockdown, further validation in diverse clinical samples would be beneficial.
  • Broader Biomarker Panel: The authors suggest that future research could focus on identifying additional DDR or RSR-associated proteins that, in combination with nuclear pCHK1, could further refine patient selection for RSR-targeted drugs. This could lead to more effective personalized cancer therapies.

Summary updated

Abstract

Excessive genomic instability coupled with abnormalities in DNA repair pathways induces high levels of 'replication stress' when cancer cells propagate. Rather than hampering cancer cell proliferation, novel treatment strategies are turning their attention towards targeting cell cycle checkpoint kinases (such as ATR, CHK1, WEE1, and others) along the DNA damage response and replicative stress response pathways, thereby allowing unrepaired DNA damage to be carried forward towards mitotic catastrophe and apoptosis. The selective ATR kinase inhibitor elimusertib (BAY 1895344) has demonstrated preclinical and clinical monotherapy activity; however, reliable predictive biomarkers of treatment benefit are still lacking. In this study, using gene expression profiling of 24 cell lines from different cancer types and in a panel of ovarian cancer cell lines, we found that nuclear-specific enrichment of checkpoint kinase 1 (CHK1) correlated with increased sensitivity to elimusertib. Using an advanced multispectral imaging system in subsequent cell line-derived xenograft specimens, we showed a trend between nuclear phosphorylated CHK1 (pCHK1) staining and increased sensitivity to the ATR inhibitor elimusertib, indicating the potential value of pCHK1 expression as a predictive biomarker of ATR inhibitor sensitivity. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
BibTeX
@article{sundararajan2022nuclear,
  author = {Vignesh Sundararajan and Tuan Zea Tan and Diana Lim and Yanfen Peng and Antje M. Wengner and Natalie Y.L. Ngoi and Anand D. Jeyasekharan and David S.P. Tan},
  title = {{Nuclear <scp>pCHK1</scp> as a potential biomarker of increased sensitivity to <scp>ATR</scp> inhibition}},
  journal = {The Journal of Pathology},
  year = {2022},
  doi = {10.1002/path.6032},
}
Figure